Signum Biosciences

Signum Biosciences

Biotechnology, 133 Wall St, Princeton, New Jersey, 08540, United States, 11-50 Employees

signumbiosciences.com

  • facebook
  • twitter
  • instagram
  • LinkedIn

phone no Phone Number: 73********

Who is SIGNUM BIOSCIENCES

Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from our phosphatase platform to modulate signal transduction imbalances....

Read More

map
  • 133 Wall St, Princeton, New Jersey, 08540, United States Headquarters: 133 Wall St, Princeton, New Jersey, 08540, United States
  • 2003 Date Founded: 2003
  • 11-50 Employees: 11-50
  • dollar-icon Revenue: $10 Million to $25 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 8731 | NAICS Code: 325414 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from SIGNUM BIOSCIENCES

Signum Biosciences Org Chart and Mapping

Employees

Lisa Johnson

Senior Vice President of Global Sales & Corporate Development

Michael Losch

Chief Financial Officer

Karl Rouzard

Director of Facilities

Kimberlee Barlow

Account Executive / Brand Development

signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

crown-icon Free credits every month

Frequently Asked Questions Regarding Signum Biosciences

Answer: Signum Biosciences's headquarters are located at 133 Wall St, Princeton, New Jersey, 08540, United States

Answer: Signum Biosciences's phone number is 73********

Answer: Signum Biosciences's official website is https://signumbiosciences.com

Answer: Signum Biosciences's revenue is $10 Million to $25 Million

Answer: Signum Biosciences's SIC: 8731

Answer: Signum Biosciences's NAICS: 325414

Answer: Signum Biosciences has 11-50 employees

Answer: Signum Biosciences is in Biotechnology

Answer: Signum Biosciences contact info: Phone number: 73******** Website: https://signumbiosciences.com

Answer: Signum Biosciences is a private biotechnology company dedicated to developing small-molecule therapeutics derived from our phosphatase platform to modulate signal transduction imbalances. Signums phosphatase technology provides many opportunities for the development of novel pharmaceutical therapeutics. Signum has established a robust IP portfolio in the area of Signal Transduction Modulators (STMs). Signal transduction networks that regulate cellular activities have built-in global control mechanisms to coordinate their many interacting components. Signum has identified agents that perturb the two most central of these global regulatory mechanisms: G-Protein-Mediated membrane receptor signaling and Protein phosphorylation. G-Protein modulators (GPMs) regulate virtually all G-protein-mediated signaling activities and Phospho-Protein modulators (PPMs) regulate protein kinase phosphorylation networks. GPMs and PPMs can be used as cosmetics and dietary supplements to correct stressful imbalances that can be detrimental to health and well-being.

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access